In some CML cases of imatinib resistance, upregulation of SRC kinase has been implicated as a BCR-ABL-independent mechanism responsible for imatinib failure [38–40]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.